文献速递胸部肿瘤支持与姑息治疗

晚期肺癌铂类化疗患者躯体与功能丧失的预测因素

Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy.
PubMed 文献 · J Thorac Oncol · 2018-07-04

POWER 1和2两项随机双盲安慰剂对照跨国III期试验共纳入600例开始化疗的肺癌患者,本研究仅对安慰剂组进行二次分析,用累积logit模型确定基线特征对化疗期间躯体与功能丧失的预测作用。结果显示约半数患者出现瘦体重和爬楼功率下降,更晚期疾病预测躯体丧失,紫杉类化疗和化疗前吸烟预测功能丧失,较高BMI为功能丧失的保护因素。

要点

  • 约50%晚期肺癌化疗患者出现瘦体重和肌肉功能持续丧失。
  • 更晚期疾病预测躯体丧失(OR=1.96;95%CI 1.14-3.36)。
  • 紫杉类化疗和化疗前吸烟预测功能丧失,较高BMI为保护因素。

核心结论

  • 约50%接受化疗的晚期肺癌患者存在肌肉量和肌肉功能持续丧失。
  • 更晚期疾病预测躯体丧失,紫杉类化疗和化疗前吸烟预测功能丧失,较高BMI为功能丧失的保护因素。
  • 所识别的躯体与功能丧失预测因素可作为治疗靶点或指导治疗努力。

研究设计与样本

  • POWER 1和2为随机双盲安慰剂对照跨国III期试验,共研究600例开始化疗的肺癌患者,旨在评估enobosarm预防和治疗肌肉丧失的疗效。
  • 本研究为限制于对照组的二次分析,使用累积logit模型分析有序结局,确定预测化疗期间躯体与功能丧失的基线特征。
  • 322例接受安慰剂的患者中,232例有可观察结局和基线协变量者纳入瘦体重分析,236例纳入爬楼功率(SCP)分析。

主要发现

  • 全部患者中53%在治疗第84天出现瘦体重丧失,49%出现爬楼功率丧失。
  • 更晚期疾病预测更高概率的更大躯体丧失(OR=1.96;95%CI 1.14-3.36)。
  • 紫杉类化疗(OR=1.73;95%CI 1.06-2.83)、化疗前吸烟(OR=2.15;95%CI 1.10-4.18)和基线SCP(OR=1.01;95%CI 1.004-1.015)预测更高概率的SCP丧失。
  • 较高体重指数为功能丧失的保护因素(OR=0.85;95%CI 0.73-0.98)。
  • 较高ECOG体能状态评分趋势上预测躯体丧失(0.767)和功能丧失(0.070)的更高概率,但结果无统计学显著性。

临床怎么用

  • 对晚期肺癌铂类化疗患者应关注肌肉量和肌肉功能丧失,尤其晚期疾病、接受紫杉类化疗或化疗前吸烟者。
  • 较高BMI与较低功能丧失风险相关,但需结合原文数据谨慎解读。

局限性

  • 本研究为对安慰剂组的二次分析,样本限于有可观察结局和基线协变量者。
  • ECOG体能状态预测结果无统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Muscle wasting has detrimental effects, including increased mortality. Identifying patients at risk can guide treatment efforts. METHODS: POWER 1 and 2 were randomized, double-blind, placebo-controlled, multinational phase III trials that studied 600 patients with lung cancer at the start of chemotherapy; the studies' aim was to assess the efficacy of enobosarm on prevention and treatment of muscle loss. We performed a secondary analysis restricted to the control group, using a cumulative logit model for ordinal outcome to determine which baseline characteristics predicted physical and functional loss during chemotherapy. RESULTS: In all, 53% of patients had loss of lean body mass and 49% had loss of stair climb power (SCP) at day 84 of treatment. Of the 322 patients who received placebo, 232 with observable outcome and baseline covariates were included for lean body mass analysis and 236 for SCP analysis. More advanced disease predicted a higher probability of greater physical loss (OR = 1.96; 95% confidence interval [CI]: 1.14-3.36). Three factors predicted higher probability of SCP loss: taxane chemotherapy (OR = 1.73; 95% CI: 1.06-2.83), tobacco use before chemotherapy (OR = 2.15, 95% CI: 1.10-4.18), and SCP at baseline (OR = 1.01, 95% CI: 1.004-1.015). Higher body mass index was a protective factor for functional loss (OR = 0.85; 95% CI: 0.73-0.98). A higher Eastern Cooperative Oncology Group Performance Status trended toward being predictive of greater probability of both physical loss (0.767) and functional loss (0.070), but the results were not statistically significant. CONCLUSIONS: Approximately 50% of patients with advanced lung cancer who were undergoing chemotherapy had ongoing loss of muscle mass and muscle function. Advanced stage predicted physical loss. Tobacco use and taxane chemotherapy predicted functional loss. Body mass index was a protective factor for functional loss. We identified predictors of physical and functional loss that could be used as therapeutic targets or to guide treatment efforts.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Kinsey E, Ajazi E, Wang X, et al. Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy. J Thorac Oncol. 2018. PMID: 29981438. doi:10.1016/j.jtho.2018.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。